Tackling care gaps in respiratory diseases in Alberta
Tackling care gaps in respiratory diseases in Alberta
Search
Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population
Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population
New initiative helps over 16,000 healthcare providers gain critical knowledge about palliative care during COVID-19
New initiative helps over 16,000 healthcare providers gain critical knowledge about palliative care during COVID-19
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Life forward - Boehringer Ingelheim unveils its evolved company brand
Ingelheim, Germany, 30/10/2023 | Boehringer Ingelheim, a leading research-driven biopharmaceutical company, on Monday presented a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners
Using AI to transform screening for type 2 diabetes
Using AI to transform screening for type 2 diabetes
New collaboration to improve the detection of type 2 diabetes in high-risk patients starts in Montreal, Quebec
The project will use artificial intelligence (A.I.), wearable technologies and electronic health record systems to identify patients who may have type 2 diabetes in Montreal, Quebec
Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD
OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients
Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients
Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients
Helping patients by addressing health system gaps
Helping patients by addressing health system gaps
Helping patients by addressing health system gaps
Helping patients by addressing health system gaps
Helping patients by addressing health system gaps
Helping patients by addressing health system gaps
Using AI to power patient-centric guideline optimization
Using AI to power patient-centric guideline optimization
Boehringer Ingelheim Canada’s national program is helping people living with diabetes and heart failure by addressing health system gaps
Boehringer Ingelheim Canada’s national program is helping people living with diabetes and heart failure by addressing health system gaps
Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario
Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario
COVID-19
COVID-19
Explore our company
Make your next career step at Boehringer Ingelheim. Explore our various fields to find out more about employment opportunities in your area of interest.
Working at Boehringer Ingelheim
Working at Boehringer Ingelheim
Leveraging Artificial Intelligence to support healthy aging
Leveraging Artificial Intelligence to support healthy aging
Optimizing oxygen needs for people living with Interstitial Lung Disease
Optimizing oxygen needs for people living with Interstitial Lung Disease
Improving the lives of Albertans with Progressive Fibrosing Interstitial Lung Disease
Improving the lives of Albertans with Progressive Fibrosing Interstitial Lung Disease
Boehringer Ingelheim - Value Through Innovation
Boehringer Ingelheim - Value Through Innovation
New partnership in Alberta supports healthcare solutions for interstitial lung diseases
New partnership in Alberta supports healthcare solutions for interstitial lung diseases
Gastrointestinal Cancers
Gastrointestinal Cancers